Columbia University Researchers Engineer Bacteria to Destroy Cancerous Tumors

Scientists at Columbia University have engineered bacteria to bypass the immune system and deliver anti-cancer drugs directly into solid tumors. The study, published in the journal Nature , demonstrates a shift toward "living medicines" designed to navigate the human body and treat localized diseases without the systemic toxicity associated with traditional chemotherapy. Targeted Delivery Mechanism The research team, led by Nicholas Arpaia and Tal Danino, utilized a modified strain of Escherichia coli (E. coli) . These bacteria were programmed to produce a synthetic coating that prevents the immune system from neutralizing them before they reach their target. Once the bacteria penetrate the tumor environment, they release therapeutic payloads, including nanobodies that activate the body’s own T-cells to attack the cancer cells. Initial testing conducted on mouse models focused on breast and colorectal cancers . Results indicated significant tumor shrinkage and, in several instances, complete remission. By confining the drug release strictly to the tumor site, the researchers avoided the widespread exposure of healthy organs to toxic compounds, potentially eliminating common side…